glp-1 antagonists Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports GLP-1 Drug Comparison in Diabetes

Animal models suggest prevention of doxorubicin-induced acute hepatotoxicity occurs via suppression of intrinsic caspase-3-dependent apoptotic signaling (24)

Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis

ISO Certified ISO certified for quality, safety, and trusted performance

Continued treatment with GLP2 for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial

Asperger's Syndrome and PDD-NOS were added to the DSM-IV in 1994 which broadened the definition to include many children who were previously undiagnosed